Patients who were treated with calcium hydroxylapatite (Radiesse, Merz Aesthetics) for dorsal hands experienced a significant improvement in appearance, according to a recent study published in Dermatologic Surgery by Mitchell Goldman, MD, and colleagues.1
For the study, Dr Goldman and his team assessed the safety and effectiveness of calcium hydroxylapatite for the correction of volume loss in the hands up to 12 months. They conducted a multicenter, controlled, single-blind study assessing 114 patients. The participants were randomized 3:1 to calcium hydroxylapatite treatment and untreated control groups.
The researchers had 3 assessments to help determine the safety and effectiveness of treatment. First, they had blinded investigators assess effectiveness using the Merz Hand Grading Scale. They also used the Global Aesthetic Improvement Scale for self-reported improvements. Further, they assessed the effects of treatment on overall hand function.
The findings showed a total of 75% of subjects achieved ≥1-point improvement on the Merz Hand Grading Scale (P< .0001) at 3 months, and this response was generally maintained through 12 months. The overall proportions of subjects who reported improvements ranged from 98% at 3 months to 86% at 12 months. The researchers reported that there were no clinically significant differences between the control group and the calcium hydroxylapatite-treated group in any hand function measure. Adverse events (AEs) were minor, short-lived, injection-related, and similar to previously reported AEs seen in other calcium hydroxylapatite clinical studies. Overall, treatment was well tolerated among participants.
Reference
Goldman MP, Moradi A, Gold MH, et al. Calcium Hydroxylapatite Dermal Filler for Treatment of Dorsal Hand Volume Loss: Results From a 12-Month, Multicenter, Randomized, Blinded Trial [Published May 25, 2017]. Dermatol Surg. DOI: 10.1097/DSS.0000000000001203.
Patients who were treated with calcium hydroxylapatite (Radiesse, Merz Aesthetics) for dorsal hands experienced a significant improvement in appearance, according to a recent study published in Dermatologic Surgery by Mitchell Goldman, MD, and colleagues.1
For the study, Dr Goldman and his team assessed the safety and effectiveness of calcium hydroxylapatite for the correction of volume loss in the hands up to 12 months. They conducted a multicenter, controlled, single-blind study assessing 114 patients. The participants were randomized 3:1 to calcium hydroxylapatite treatment and untreated control groups.
The researchers had 3 assessments to help determine the safety and effectiveness of treatment. First, they had blinded investigators assess effectiveness using the Merz Hand Grading Scale. They also used the Global Aesthetic Improvement Scale for self-reported improvements. Further, they assessed the effects of treatment on overall hand function.
The findings showed a total of 75% of subjects achieved ≥1-point improvement on the Merz Hand Grading Scale (P< .0001) at 3 months, and this response was generally maintained through 12 months. The overall proportions of subjects who reported improvements ranged from 98% at 3 months to 86% at 12 months. The researchers reported that there were no clinically significant differences between the control group and the calcium hydroxylapatite-treated group in any hand function measure. Adverse events (AEs) were minor, short-lived, injection-related, and similar to previously reported AEs seen in other calcium hydroxylapatite clinical studies. Overall, treatment was well tolerated among participants.
Reference
Goldman MP, Moradi A, Gold MH, et al. Calcium Hydroxylapatite Dermal Filler for Treatment of Dorsal Hand Volume Loss: Results From a 12-Month, Multicenter, Randomized, Blinded Trial [Published May 25, 2017]. Dermatol Surg. DOI: 10.1097/DSS.0000000000001203.
Patients who were treated with calcium hydroxylapatite (Radiesse, Merz Aesthetics) for dorsal hands experienced a significant improvement in appearance, according to a recent study published in Dermatologic Surgery by Mitchell Goldman, MD, and colleagues.1
For the study, Dr Goldman and his team assessed the safety and effectiveness of calcium hydroxylapatite for the correction of volume loss in the hands up to 12 months. They conducted a multicenter, controlled, single-blind study assessing 114 patients. The participants were randomized 3:1 to calcium hydroxylapatite treatment and untreated control groups.
The researchers had 3 assessments to help determine the safety and effectiveness of treatment. First, they had blinded investigators assess effectiveness using the Merz Hand Grading Scale. They also used the Global Aesthetic Improvement Scale for self-reported improvements. Further, they assessed the effects of treatment on overall hand function.
The findings showed a total of 75% of subjects achieved ≥1-point improvement on the Merz Hand Grading Scale (P< .0001) at 3 months, and this response was generally maintained through 12 months. The overall proportions of subjects who reported improvements ranged from 98% at 3 months to 86% at 12 months. The researchers reported that there were no clinically significant differences between the control group and the calcium hydroxylapatite-treated group in any hand function measure. Adverse events (AEs) were minor, short-lived, injection-related, and similar to previously reported AEs seen in other calcium hydroxylapatite clinical studies. Overall, treatment was well tolerated among participants.
Reference
Goldman MP, Moradi A, Gold MH, et al. Calcium Hydroxylapatite Dermal Filler for Treatment of Dorsal Hand Volume Loss: Results From a 12-Month, Multicenter, Randomized, Blinded Trial [Published May 25, 2017]. Dermatol Surg. DOI: 10.1097/DSS.0000000000001203.
